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We used positron emission tomography with I ' 'Clflumazenil to study gamma-aminobutyric acid type Albenzodiaze- 
pine receptor binding quantitatively in the cerebral hemispheres, basal ganglia, thalamus, cerebellum, and brainstem 
of 72 subjects, including 14 with multiple system atrophy of the ataxic (olivopontocerebellar atrophy) type, 5 with 
multiple system atrophy of the extrapyramidaUautonomic (Shy-Drager syndrome) type, 18 with sporadic olivoponto- 
cerebellar atrophy, 15 with dominantly inherited olivopontocerebellar atrophy, and 20 normal control subjects with 
similar age and sex distributions. In comparison with data obtained from the normal control subjects, we found 
significantly decreased ligand influx in the cerebellum and brainstem of multiple system atrophy patients of the 
olivopontocerebellar atrophy type and in patients with sporadic olivopontocerebellar atrophy, but not in patients with 
multiple system atrophy of the Shy-Drager syndrome type. Despite these differences in ligand influx, benzodiazepine 
binding was largely preserved in the cerebral hemispheres, basal ganglia, thalamus, cerebellum, and brainstem in 
patients with multiple system atrophy of both types as well as those with sporadic or dominantly inherited olivoponto- 
cerebellar atrophy as compared with normal control subjects. The finding of relative preservation of benzodiazepine 
receptors indicates that these sites are available for pharmacological therapy in these disorders. 
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Gamma-aminobutyric acid (GABA) is an inhibitory 
neurotransmitter located abundantly in the central ner- 
vous system (CNS) [l, 2). Most GABAergic neurons 
are interneurons, but some such as Purkinje cells and 
striatonigral, nigrothalamic, and nigrotectal neurons are 
principal output neurons. Two types of receptor sites 
mediate GABAergic neurotransmission, GABA, and 
GABA,. The action of the GABAA receptor is the 
opening of chloride channels [3, 41. Low- and high- 
affinity GABA, receptor binding sites exist in the 
mammalian central nervous system 15-31. Low-affinity 
GABA, receptors contain at least three binding sites 
for pharmacologically specific agents, including benzo- 
diazepines (BDZ), barbiturates, and convulsants [2, 3 ,  
10, 111. These sites are functionally coupled to one 
another, residing on the oligomeric protein complex 
that regulates chloride ion permeability 121. The recent 
development of a BDZ ligand, [ "C1flumazenil (FMZ), 
that can be used with positron emission tomography 
(PET) makes it possible to measure the density of 
GABA,/BDZ receptors in the central nervous system 
of patients with disorders that affect neurons contain- 
ing these receptors [I?-141. 
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Multiple system atrophy (MSA) is a progressive neu- 
rodegenerative disease presenting with combinations 
of extrapyramidal, pyramidal, cerebellar, and auto- 
nomic symptoms and signs [15-18). Some patients 
with MSA have extrapyramidal and autonomic symp- 
toms (Shy-Drager syndrome [SDS]). Others have only 
extrapyramidal symptoms unresponsive to levodopa 
throughout their course (striatonigral degeneration 
[SND]), but in most of these patients, neuropathologi- 
cal examination demonstrates degenerative changes in 
the cerebellum and brainstem [ 191. Another pattern is 
initial extrapyramidal symptoms with the later develop- 
ment of cerebellar symptoms, with or without auto- 
nomic symptoms Cl51.Other patients first manifest cer- 
ebellar symptoms at which time they might be thought 
clinically to have sporadic olivopontocerebellar atrophy 
(sOPCA), but later they develop autonomic or extrapy- 
ramidal symptoms and then fall into the diagnostic cat- 
egory of MSA. The neuropathological changes in MSA 
include those seen in S N D  120-231, SDS [ 17,24-271, 
and OPCA 117-191. Neuronal loss and gliosis occur 
in the basal ganglia (putamen and globus pallidus), 
brainstem and cerebellum (substantial nigra, locus ce- 
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ruleus, dorsal vagal nuclei, vestibular nuclei, inferior ol- 
ives, pontine nuclei, cerebellar Purkinje cells), and spi- 
nal cord (pyramidal tracts, intermediolateral columns 
and Onuf's nuclei) [ l 5 ,  18, 191. Many of the structures 
affected contain neurons with GABAAIBDZ recep- 
tors. Recently, oligodendroglial C28-32) and neuronal 
[33-351 intracytoplasmic and intranuclear inclusions 
have been found in MSA. 
OPCA is a progressive neurological disorder charac- 
terized by degeneration of neurons. in the inferior ol- 
ives, pons, and cerebellum occurring both sporadically 
and with hereditary transmission [36-401. When he- 
reditary, the disease is usually expressed as an autoso- 
mal dominant trait, but at times as an autosomal reces- 
sive trait [39, 403. A locus on chromosome 6 was 
identified in some families with dominantly inherited 
OPCA [4 11, and loci also were found on chromosomes 
12, 14, and 16 in other families. Most patients become 
symptomatic in middle age with progressive ataxia of 
gait and speech, disturbances of extraocular move- 
ments, and difficulty with limb coordination. The neu- 
ropathological changes include loss of inferior olivary 
neurons and their climbing fiber projections to the cer- 
ebellum, and loss of pontine neurons and their mossy 
fiber connections in the cerebellum [ l 8 ,  42-44]. Pur- 
kinje cells are severely reduced but not completely 
lost, and granule cells are reduced. Golgi cells are prob- 
ably unaffected, and basket cells are relatively pre- 
served. Dentate neurons also are preserved. Many of 
the neurons affected in OPCA contain GABAA/BDZ 
receptors. In some patients, OPCA evolves clinically 
into MSA and patients show degenerative changes 
within the basal ganglia and spinal cord [ 15- 177. Most 
patients who present initially with OPCA and later de- 
velop clinical manifestations of MSA have a sporadic 
and not a hereditary form of the disorder [ l 6 ] .  It is 
unclear whether all patients with sOPCA progress to 
develop MSA. In the present study, we separated pa- 
tients into OPCA and MSA groups based on clinical 
criteria provided in the Materials and Methods section. 
The present study was initiated to examine BDZ 
receptors in the cerebellum of patients with MSA, 
sOPCA, and dominantly inherited OPCA (dOPCA) in 
comparison with normal control subjects with similar 
age and sex distributions, to determine whether these 
receptors are preserved in these disorders. The pa- 
tients with MSA were further subdivided into those 
with the ataxic (olivopontocerebellar atrophy) type 
(MSAOPCA) and those with the extrapyramidal/auto- 
nomic (SDS) type (MSASDS). We were interested in 
BDZ receptors because differences in BDZ receptor 
density may ( 1 )  give insights into the pathogenesis of 
these disorders, (2)  suggest new approaches to diagno- 
sis, and ( 3 )  indicate whether GABAA/BDZ receptors 
are available for potential pharmacological interven- 
tions in these disorders. 
Materials and Methods 
Patient Groups and Normal Subjects 
The studies were approved by the Institutional Review 
Board, and informed consent was obtained from each sub- 
ject. Five groups of subjects were studied: (1) MSAO,,, 
(2) MSA,,,, (3) sOPCA, and (4) dOPCA patients, and (5) 
normal control subjects (Table 1). We studied 72 subjects 
(52 patients and 20 normal control subjects), mean age 56 
* 13 years ( 2  standard deviation), including 36 women (9 
normal control subjects and 27 patients), mean age 54 2 14 
years, and 36 men (1 1 normal control subjects and 25 pa- 
tients), mean age 58 ? 12 years (see Table l). Significant 
differences in age were found among the five diagnosis 
groups ( p  < 0.0005) with a single factor analysis of variance 
(ANOVA). Three patients, 2 with sOPCA and 1 with 
dOPCA, were included from our previous positron emission 
tomography (PET) studies of glucose metabolic rate with 
["F)fluorodeoxyglucose (FDG) [45-47). One of the 2 pa- 
tients with sOPCA in the previous communications devel- 
oped extrapyramidal and autonomic symptoms and signs sub- 
sequent to the initial study and is now included in the 
MSA,, group. In our analysis of the duration of symp- 
toms, we report the median and range rather than the mean 
and standard deviation because the distributions are skewed. 
For the MSAOpcA group the duration ranged from 2 to 11 
years with a median of 5 years; for the MSAsDs group the 
range was 2 to 16 years with a median of 7 years; for the 
sOPCA group, the range was 1 to 20 years with a median of 
4.5 years; and for the dOPCA group, the range was 2 to 20 
years with a median of 5 years. The normal control subjects 
had no history of neurological disorder and no abnormalities 
on general physical and neurological examinations. At the 
time of the PET study, none of the patients or normal control 
Table 1. Numbers, Ages (mean t stanahrd deviation), and Sex Distribution of the Subjects Studied 
Normal Controls MSAOPCA MSASDS sOPCA dOPCA 
n Age (yr) n Age ( y d  n Age (yr) n Age (yr) n Age (yr) 
Men 11 61 2 12 7 6 4 2 5  4 64 2 12 7 56 t 12 7 47 ? 14 
Women 9 6 1 2 9  7 6 3 2 9  1 67 11 45 t 15 8 51 ? 14 
Total 20 61 2 10 14 64 5 7 5 65 2 11 18 49 t 15 15 49  ? 13 
MSA = multiple system atrophy; MSA,,,, = MSA group with cerebellar and autonomic or cerebellar, extrapyramidal, and autonomic signs; 
MSA,,, = MSA group with extrapyramidal and autonomic signs only; sOPCA = sporadic olivopontocerebellar atrophy; dOPCA = dominantly 
inherited olivoponrocerebellar atrophy. 
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subjects were taking medications that are known to influence 
BDZ receptors. Five of the MSA patients had been treated 
with BDZ (diazepam, chlordiazepoxide, or clonazepam), but 
these medications had been discontinued for 6 weeks before 
the PET study in 2 patients and for 1 to 3 years in the other 
3. Two of the dOPCA patients had been treated with BDZ 
(chlordiazepoxide or clonazepam), and these medications 
were discontinued 6 weeks and 1 year prior to PET study. 
Three of the patients with sOPCA had been treated with 
BDZ (clonazepam), and these medications had been discon- 
tinued for 6 weeks to 2 years prior to PET study. All 5 of the 
MSASDs patients were taking medications for parkinsonism 
(carbidopa/levodopa 25/100 mg or 25/250 mg, three or four 
times daily). 
Of the 19 patients with MSA, utilizing the criteria of 
Quinn [l5}, we made the diagnosis of probable MSA in 15 
and definite MSA (autopsy verified) in 4. The diagnosis of 
probable MSA was based on demonstration of clinical signs 
of at least two of the following: ( 1 )  extrapyramidal disorder, 
(2) autonomic failure, and (3) cerebellar dysfunction. For the 
demonstration of extrapyramidal disorder, we required at 
least two of the following signs: akinesia, rigidity, tremor, 
and hypokinetic speech. Tremor was accepted as an extrapy- 
ramidal sign only if it was present at rest and involved distal 
parts of the limbs. With these criteria, we found that 16 of 
the 19 patients had extrapyramidal disorders. In 12 of the 
16, we also assessed the degree of responsiveness to levo- 
dopa with clinical neurological evaluations before and after 
treatment with carbidopallevodopa at a dose of 251250 mg, 
gradually increased from one to four tablets daily. Patients 
were judged to be unresponsive or mildly, moderately, or 
markedly responsive. Nine of the 12 tested were unrespon- 
sive, 1 was mildly responsive, 1 was moderately responsive, 
and 1 was markedly responsive. The remaining 4 patients 
could not be tested because they were referred to us from dis- 
tant locations. The demonstration of changes in the putamen 
in magnetic resonance (MR) scans 148,493 provided helpful 
information for the diagnosis of MSA but was not required 
since these changes are not consistently present in MSA 1501. 
For the demonstration of cerebellar dysfunction, we re- 
quired at least two signs, including limb andlor gait ataxia 
along with ocular dysmetria or ataxic dysarthria. We found 
that 14 of the 19 MSA patients had cerebellar dysfunction. 
For the demonstration of autonomic failure, we required pos- 
tural hypotension, sexual impotence (in the males), or urinary 
incontinence without outflow obstruction. The criteria for 
postural hypotension were similar to those of McLeod and 
Tuck [Sl] ,  including an orthostatic drop of 30 mm Hg or 
more in systolic blood pressure and 20 mm H g  or more in 
diastolic blood pressure with an increase in heart rate of no 
more than 10 beatslmin. Blood pressure and pulse were mea- 
sured with the patient supine and again 2 minutes after the 
patient had assumed the standing position. In patients who 
could not tolerate standing for 2 minutes, these changes were 
accepted after the patient stood as long as tolerated. None 
of the patients were taking medications that induce postural 
hypotension except for carbidopallevodopa, which was ad- 
ministered to 5 MSASDS patients. Eleven of the 19 patients 
with MSA had postural hypotension, 15 of the 19 had urinary 
incontinence, 9 of the 19 had both postural hypotension and 
urinary incontinence, and 10 of 11 male patients had sexual 
impotence. All 19 patients had at least one of the criteria for 
autonomic insufficiency. In summary, 11 of the 19 patients 
with MSA had extrapyramidal, cerebellar, and autonomic 
dysfunction; 5 had extrapyramidal and autonomic distur- 
bances; and 3 had cerebellar and autonomic disorders. The 
5 with extrapyramidal and autonomic disturbances consti- 
tuted the MSAsDs group; the other 14, in whom cerebellar 
dysfunction dominated, made up the MSAoKA group. 
The diagnosis of OPCA was based on a history of progres- 
sive deterioration in cerebellar function manifested by ataxia 
of gait and speech, usually accompanied by ataxia of ocular 
and limb movements, in the absence of a disorder of sensory 
function sufficient to cause ataxia, medications (e.g., pheny- 
toin), toxins (e.g., alcohol), evidence of a neoplasm in the 
cerebellum or elsewhere, or evidence of multiple sclerosis 
or other diseases that can cause progressive cerebellar ataxia. 
The diagnosis was assisted by the demonstration of cerebellar 
and brainstem atrophy in computed tomography (CT) or MR 
scans, but this was not required since OPCA can occur in 
the absence of atrophy on anatomical imaging studies 1451. 
Each patient was evaluated with a complete history, physi- 
cal examination, neurological examination, laboratory tests to 
exclude other diseases, and MR imaging to exclude demye- 
linative disease and structural abnormalities. Speech was evalu- 
ated as described previously 147). Laboratory tests included 
a complete blood cell count; serum profiles of hepatic and 
renal function; brainstem auditory, visual, and somatosensory 
evoked potentials; serum levels of vitamins E and B,, and 
folic acid; and studies of thyroid function. In patients with 
symptoms for less than 3 years, a search was made for an 
occult malignancy, including breast and pelvic examinations 
in women, prostate examination in men, measurement of 
acid phosphatase and prostate-specific antigen levels, stool 
guaiac tests for occult blood, and chest x-ray films. In addi- 
tion, anti-Purkinje cell antibodies were sought in blood sam- 
ples for patients with ataxia of less than 3 years' duration. All 
patients were evaluated with MR imaging to determine the 
extent of volume loss of the structures under study. The 
diagnosis of sOPCA was made if there was no family history 
of a similar illness after a detailed history had been taken 
with construction of a family tree. The diagnosis of dOPCA 
was based on a clear family history of a similar disorder in at 
least one parent. Patients with a family history suggesting 
autosomal recessive inheritance were excluded from this 
study. 
The neurological examinations were conducted by a neu- 
rologist (S. G.)  blinded to the PET data. Speech was evalu- 
ated by a speech-language pathologist (K. J. K.) also blinded 
to the results of the PET studies. 
Positron Emission Tomography Studies 
PET studies were conducted similarly for all subjects. The 
subjects were fasted for 4 hours before scanning. A catheter 
was placed in a radial artery for blood sampling. The subjects 
lay quietly on a table, eyes open, ears unoccluded, and alert 
but not speaking. Scans were performed after intravenous 
injection of ["C)FMZ in patients with MSA, sOPCA, 
dOPCA, and normal control subjects. 
The subjects were imaged with a SiemendCTI 931/08-12 
scanner, which has an intrinsic in-plane resolution of 5.5-mm 
full-width at half-maximum (FWHM) at the center of the 
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field of view and an axial resolution of 7.0-mm FWHM. The 
reconstructed resolution is 9.0-mm FWHM at the center of 
the field of view. Fifteen planes with a 6.75-mm center-to- 
center separation were imaged simultaneously. Attenuation 
correction was calculated by the standard ellipse method. The 
PET studies were analyzed with a compartmental model and 
parameter estimation technique that provides pixel-by-pixel 
determinations of each measurement, thus creating "func- 
tional" images (131. 
We labeled FMZ with "C at high specific radioactivity 
using a methylation process (12) and administered a dose of 
22 4 2 mCi. Blood samples were taken as rapidly as possible 
during the first 2 minutes after tracer injection and then at 
progressively longer intervals throughout the remainder of 
the study. We took a total of 25 to 30 samples per scan. 
The samples were centrifuged, and the plasma radioisotope 
concentrations were measured in an NaI well counter. 
Plasma levels of radiolabeled metabolites of [ "C)FMZ were 
determined by a rapid Sep-Pak C18 cartridge chromato- 
graphic technique 1141 in the samples taken at 1 minute and 
2 minutes, and every sample from 3 minutes until the end 
of the scan. Dynamic PET scanning was performed for 60 
minutes beginning immediately after injection. Radioactive 
fiducials with 5 FCi of ("CIFMZ were placed on each sub- 
ject's scalp. Computer routines automatically determined the 
locations of these fiducials and used this information to cor- 
rect for patient motion. The studies with ["CIFMZ were 
performed to measure ligand influx (K1), which is highly cor- 
related with flow since the single-pass extraction fraction is 
greater than 50% (131. The studies were also performed to 
measure ligand distribution volume (DV), which is linearly 
related to the density of available receptor sites divided by 
the ligand dissociation constant (Emu'/KD). The methods of 
using 1 "C)FMZ for BDZ receptor binding, including the 
assumptions and limitations and the performance of the 
agent, are published (13, 14, 527. 
A data analyst (M. L.) extracted volume of interest (VOI) 
information from the PET studies, and these data were 
shared among the investigators only after completion of mea- 
surements from all studies. The process of data extraction is 
almost completely automated, requiring essentially no judg- 
ments by the data analyst. For VOI placement we utilized 
templates developed previously (45-47, 53). The PET stud- 
ies were displayed as two image sets (one each for FMZ K ,  
and DV). VOIs were identified in the identical areas from 
each matched set. VOI data were acquired from the cerebral 
cortex, caudate nucleus, putamen, thalamus, cerebellar hemi- 
spheres, cerebellar vermis, and brainstem. Although study of 
the cerebellar nuclei would be of interest, the binding in 
this structure with FMZ was not sufficient to allow accurate 
measurement. PET images were viewed in the transverse, 
sagittal, and coronal planes. Each pixel measures 1.875 x 
1.875 mm. Data from the cerebral cortex were obtained in 
transverse images by measuring K ,  and DV in the cortical 
ribbon from four or five consecutive planes of 15, beginning 
with the plane containing the most superior portion of the 
cingulate gyrus and continuing ventrally to the plane con- 
taining the lowest portion of the thalamus. This was accom- 
plished with an algorithm that detects the outer edge of the 
cortical rim from an image that has been passed through 
a contrast-enhancing filter. The algorithm then identified a 
cortical band on the original image that extends inward from 
this edge until the DV drops below the value on the outer 
edge of the rim or the band reaches a width of 15 mm. For 
analysis of the basal ganglia, data were obtained from a 0.9- 
cm2 square over the caudate nucleus of each side from 2 of 
the 15 levels, a 1.9-cm2 parallelogram over each putamen 
from 2 of the 15 levels, and a 1.3-cmZ parallelogram over 
the thalamus of each side from 2 of the 15 levels. For the 
cerebellum, data were collected from two slices utilizing im- 
ages obtained in the transverse plane with a 2.6-cm2 polygon 
over each cerebellar hemisphere. Data were collected from 
the cerebellar vermis posterior to the fourth ventricle utiliz- 
ing a 6 x 10 x 7-voxel parallelepiped on a midsagittal slice. 
Data were collected in the midsagittal plane from the pons 
with a 1.3 x 1.5 x 1.1-cm right parallelepiped. Each VOI 
was centered over a local peak in K1. 
Data Analysis 
The data were analyzed in several stages. In the first stage, 
not presented here, plots of the data were used to assess 
gross trends and relationships between variables. Second, a 
multivariate repeated measures analysis of covariance (MAN- 
COVA) model was fitted to the data incorporating region 
as the repeated (within-subject) measures variable, diagnosis 
group, sex, and age, and all of the interactions among these 
variables to determine whether differences exist between 
brain regions. In the multivariate analysis, the dependent 
variable was regional brain K1 or DV (either absolute or 
normalized). Measurements on seven (or six) brain regions 
constituted the repeated measurements on each patient for 
absolute (or normalized) data. The primary independent vari- 
able in the analysis was the categorical variable diagnosis 
group (MSA,,.,, MSASDS, sOPCA, dOPCA, or normal con- 
trol). The factor sex and the continuous covariate age also 
were included in the model. All possible interactions be- 
tween diagnosis group, sex, and age were considered. Age 
was standardized by subtracting the mean age across all sub- 
jects. 
Depending on the outcome of the analysis in the second 
stage, a univariate ANOVA or ANCOVA model was devel- 
oped to examine each region separately. The factors incorpo- 
rated into the univariate model were those identified in the 
second stage as having an overall effect on K, or DV across 
regions or having a differential effect on K ,  or DV between 
regions. In the last stage, comparisons of individual diagnosis 
group means were made where appropriate. For all pairwise 
differences a Bonferroni multiple comparison adjustment 
(541 was used. With five diagnosis groups under comparison, 
examination of all comparisons among the age-ad justed 
group means provided 10 comparisons, which was the Bon- 
ferroni factor used throughout. Data were analyzed with the 
SAS statistical package (SAS Institute, Cary, NC). 
Results 
Flumazenil Ligand ln$ux 
We studied FMZ influx (K,) (Fig 1) using both abso- 
lute values (Table 2) and values normalized to the 
whole brain cerebral cortex (Table 3). In the multivari- 
ate repeated MANCOVA of absolute K,, we found 
no evidence for differential effects of age by region or 
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Fig  1. Positron emission tomography scans with {"C}fluma- 
zenil shouhzg ligand infrzx (K,) in a male normal control sub- 
ject aged 53 years (left upper image), a male patient aged 71 
years with multiple system atrophy (MSA, right upper image) 
of the ataxic (olivopontocerebelkzr atrophy) type. a male patient 
aged 63 years with sporadic oliz,opontocerebellar atrophy 
(sOPCA, left lower image), and a male patient aged 60 years 
with dominantly inherited olivopontocrrebellar atrophy 
(dOPCA, right lower image). All scans show horizontal sec- 
tions at the level of the cerebellum and the base ofthe temporal 
and frontal lobes. The scam show decreased influx in the cerebel- 
lum and braimtem in M S A  and sOPCA and in the cerebellum 
in dOPCA in compariJ.on with the normal subject. 
F i g  2. Positron emission tomography scam with { "C}fluma- 
zenil showing ligand distribution solume (DV, in the same sub- 
jects shown in Figure 1: a male normal control subject aged 53 
years (left upper image), a male patient aged 71 years with 
multiple system atrophy (MSA, right upper image) of the 
ataxic (olivopontocerebellar atrophy) type. a male patient aged 
63 years with sporadic olioopontocerebellar atrophy (sOPC A, 
left lower image), and a male patient aged 60 years with dom- 
inantly inherited olivopontocerebellar atrophy (dOPCA, right 
lower image). All scans show horizontal sections at the leuel of 
the cerebellum and the base of the temporal and frontal lobes. 
The color bar indicates {"C)flumazenil DV in milliliters per 
gram. The scans show essentially equal DV in the patients as 
compared with the normal subject. 
Table 2. Flumazenil Influx ( K l ) ,  Absolute Leaels (IN mllgnilmin, mean t standard error)a 
Normal 
Controls MSAOPC.4 MSASDS sOPCA dOPCA 
Structure (n = 20) (n = 14) (n = 5 )  (n = 18) (n = 1 5 )  
Cerebral cortex 0.29 t 0.01 0.31 2 0.02 0.30 f 0.03 0.29 5 0.01 0.32 f 0.02 
Caudate nuclei 0.36 t 0.02 0.37 5 0.03 0.37 f 0.04 0.34 2 0.02 0.40 ? 0.02 
Putamen 0.38 f 0.02 0.39 2 0.03 0.42 f 0.04 0.37 2 0.02 0.42 t 0.02 
0.25 2 0.03b 0.36 ? 0.05 0.25 5 0.02' 0.34 f 0.02 
0.43 f 0.02 0.46 * 0.04 0.47 f 0.05 0.41 2 0.02 0.47 t 0.03 Thalamus 
Cerebellar hemispheres 0.37 I? 0.02 
Brainstem 0.33 :? 0.02 0.24 2 0.03 0.37 ? 0.04 0.25 t 0.02b 0.31 f 0.02 
aAbbreviarions are as in Table 1. 
'Significantly different from normal controls at p < 0.05. 
'Significanrly different Irom normal controls at p < 0.005. 
'Significant difference berween MSA,,, and sOPCA at p < 0.05. 
'Significantly different from normal controls at p < 0.001. 
Cerebellar vermis 0.35 t 0.02 0.27 2 0.02 0.38 f 0.04d 0.25 2 0.02".' 0.32 2 0.02 
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Table 3. Flumazenil lnjlux ( K ] ) ,  Normalized to the Cerebral Cortex (mean f standard error)" 
Structure 
~ 
Normal 
Controls MSAOPCA MSASDS sOPCA 
(n = 20) (n = 14) (n = 5) (n = 18) (n  = 15) 
dOPCA 
Caudate nuclei 1.24 f 0.03 1.20 2 0.05 1.23 2 0.07 1.17 f 0.03 1.23 f 0.03 
Putamen 1.33 f 0.02 1.27 * 0.04 1.40 f 0.06 1.29 f 0.03 1.31 5 0.03 
Thalamus 1.50 5 0.03 1.49 +- 0.06 1.57 ? 0.08 1.42 * 0.04 1.46 f 0.04 
Cerebellar hemispheres 1.27 f 0.05 0.81 f 0.08b 1.18 f 0.12 0.88 2 O.OSb 1.05 f 0.06' 
Cerebellar vermis 1.22 f 0.04 0.88 f O.Obdse 1.25 f 0.09'*' 0.87 ? 0.04b.f 0.99 * 0.059 
Brainstem 1.13 f 0.04 0.80 f 0.07e*g 1.23 f O.ll'*h 0.85 2 0.05b.h 0.98 f 0.05 
'Abbreviations are as in Table 1. 
'Significantly different from normal controls at p < 0.0001. 
'Significantly different from normal controls at p < 0.05. 
dSignificantly different from normal controls at p < 0.001. 
'Significant difference between MSAopcA and MSAsDs at p < 0.05. 
'Significant difference between MSASDS and sOPCA at p < 0.005. 
Kgnificantly different from normal controls at p < 0.005. 
hSignificant difference between MSAsDs and sOPCA at p < 0.05. 
sex by region, nor evidence for differential effects of 
interactions among these factors and diagnosis by re- 
gion. Strong evidence was obtained for differences in 
regions ( p  < 0.0001) and for differential effects of 
diagnosis by region. Further (univariate) analysis of in- 
dividual regions, adjusted for age and age by diagnosis 
interactions, revealed highly significant differences be- 
tween the five diagnostic groups in the cerebellar hemi- 
spheres ( p  = 0.001) and cerebellar vermis ( p  = 
0.001). A significant difference was found in brainstem 
( p  = 0.005) as well. N o  differences among diagnostic 
groups were found in the cerebral cortex, caudate nu- 
cleus, putamen, or thalamus ( p  > 0.10). 
As indicated in Table 2, pairwise comparisons of 
age-adjusted means for the groups found to differ as 
described above (cerebellar hemispheres, cerebellar 
vermis, and brainstem), corrected with a Bonferroni 
adjustment, revealed significantly decreased absolute 
K ,  in the cerebellar hemispheres ( p  < 0.005), cerebel- 
lar vermis ( p  < 0.001), and brainstem ( p  < 0.05) in 
sOPCA patients compared to normal control subjects. 
The analysis also showed significantly decreased abso- 
lute K ,  in the cerebellar hemispheres ( p  < 0.05) in 
MSA,,,, patients compared to normal control sub- 
jects and in the cerebellar vermis ( p  < 0.05) in sOPCA 
compared to MSAsDs patients. 
Analysis of K ,  normalized to cerebral cortex re- 
vealed no evidence for differential effects of sex or 
age by region, nor evidence for differential effects of 
interactions between sex and diagnosis or age by re- 
gion. Strong evidence was found for differences in re- 
gions ( p  < 0.0001) and differential effects of diagnosis 
by region ( p  < 0.003). Further analysis of individual 
regions, adjusted for age and age by diagnosis inter- 
actions, demonstrated highly significant differences 
between the five diagnostic groups in the cerebellar 
hemispheres ( p  < 0.00001), cerebellar vermis ( p  < 
O.OOOOl), and brainstem ( p  = 0.00001). No other 
regions exhibited significant differences in diagnostic 
groups ( p  > 0. lo). 
Individual Bonferroni-ad justed comparisons of age- 
adjusted mean normalized K, values (see Table 3 )  re- 
vealed a significant decrease of influx in the cerebellar 
hemispheres ( p  < O.OOOl), cerebellar vermis ( p  < 
0.001), and brainstem ( p  < 0.005) in MSAop,, pa- 
tients in comparison to normal subjects. A significant 
decrease of K ,  was found in these same three regions 
(all p < 0.0001) in sOPCA patients in comparison to 
normal control subjects. A significant decrease of K ,  
was found only in the cerebellar hemispheres ( p  < 
0.05) and cerebellar vermis ( p  < 0.05) in dOPCA 
patients in comparison to normal control subjects. A 
significant decrease of K1 was found in the cerebellar 
vermis and brainstem ( p  < 0.0s) in MSAOp,, in com- 
parison to MSASDS patients, and a significant decrease 
of K ,  was found in the cerebellar vermis ( p  < 0.005) 
and brainstem ( p  < 0.05) in sOPCA in comparison to 
MSA,,, patients. 
Flumazenil Ligand Distribution Volume 
In the multivariate repeated MANCOVA of absolute 
DV, we found no evidence of differences among the 
diagnostic groups (Fig 2). We found neither an average 
diagnosis effect nor a differential diagnosis effect by 
region. Univariate ANCOVA adjusted for age and age 
by diagnosis interactions supported this finding 
(Table 4). 
Analysis of DV values normalized to the cerebral 
cortex provided evidence for a differential effect of 
diagnosis by region as well as age by diagnosis by re- 
gion interaction. No average effect of diagnosis across 
all regions was apparent. Subsequent univariate analy- 
ses of each region disclosed differences between diag- 
nostic groups only in the cerebellar vermis ( p  = 0.01). 
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Table 4. Flumazenil Distribution Volume, Absolute Levels (in mllgm, mean ? standrrd 
Normal 
Controls MSAOPCA MSASDS sOPCA dOPCA 
Structure (n = 20) (n = 14)  (n = 5 )  (n = 18) (n = 1 5 )  
5.70 ? 0.49 5.58 -t 0.22 5.52 +- 0.24 Cerebral cortex 5.23 ? 0.20 5.45 f 0.33 
Caudate nuclei 3.07 ? 0.18 3.23 2 0.30 3.07 ? 0.45 3.25 ? 0.20 3.10 +- 0.22 
3.91 ? 0.25 3.69 ? 0.37 3.75 2 0.16 3.61 2 0.18 Putamen 3.51 ? 0.15 
Thalamus 3.59 ? 0.14 3.70 2 0.23 3.74 ? 0.34 3.64 & 0.15 3.68 ? 0.17 
Cerebellar hemispheres 4.06 ? 0.24 4.74 ? 0.38 4.39 ? 0.58 4.29 +- 0.26 4.26 +- 0.28 
Brainstem 1.14 rfr 0.05 1.12 -t 0.08 1.27 ? 0.13 1.12 5 0.06 1.14 2 0.06 
Cerebellar vermis 3.58 % 0.17 3.67 ? 0.28 3.84 ? 0.43 3.17 -+ 0.19 3.39 * 0.21 
“No significant differences were found between regions. Abbreviations are as in Table 1. 
Bonferroni-ad justed pairwise comparisons of age- 
adjusted means for each diagnostic group revealed sig- 
nificantly decreased DV in the cerebellar vermis ( p  < 
0.01) in sOPCA patients relative to normal control 
subjects (Table 5) .  
A power analysis was undertaken to determine 
whether .the normal DV in all patient groups within all 
regions (except for the cerebellar vermis in sOPCA 
patients) was due to the limited number of subjects 
available. Using the estimated standard deviations and 
age-adjusted normal control means from these data, 
we examined the probability of detecting a 20% de- 
crease in FMZ DV relative to normal control values 
for each region and diagnosis group for a test at ct = 
0.05. For absolute data obtained from the cerebellar 
vermis, the power was 0.85 in sOPCA patients relative 
to normal control subjects, 0.81 for dOPCA patients, 
0.80 for MSAopCA patients, and 0.48 for MSAsDs pa- 
tients. The power for the other regions in sOPCA pa- 
tients ranged from a minimum of 0.69 for cerebral 
cortex to a maximum of 0.97 for caudate nucleus. For 
other diagnostic groups, the power ranged from 0.65 
to 0.95 for dOPCA, 0.63 to 0.94 for MSAopc,, and 
0.34 to 0.68 for MSAsDs. For normalized data obtained 
from the cerebellar vermis, the power was 0.98 for 
sOPCA, dOPCA, and MSAopcA patients, and 0.78 for 
MSAsDs patients. The caudate nucleus was the region 
with the lowest power: 0.91 for sOPCA, 0.88 for 
dOPCA, 0.86 for MSAOpCA, and 0.55 for MSASDS pa- 
tients. Thus, the lack of statistically significant differ- 
ences in DV for most regions in most patient groups 
cannot be attributed to low power. 
Discussion 
This study demonstrated significantly decreased abso- 
lute levels of FMZ influx (K,) in the cerebellar hemi- 
spheres of patients with MSAopcA as compared with 
normal control subjects; in the cerebellar hemispheres, 
cerebellar vermis, and brainstem of patients with 
sOPCA in comparison with normal control subjects; 
and in the cerebellar vermis of patients with sOPCA 
in comparison with MSAsDs patients. FMZ influx nor- 
malized to the cerebral cortex was significantly de- 
creased in the cerebellar hemispheres and cerebellar 
vermis of patients with MSAopcA, sOPCA, or dOPCA, 
but not in patients with MSAsDs as compared with 
normal control subjects. FMZ influx normalized to the 
cerebral cortex was also significantly decreased in the 
brainstem of patients with MSAopcA or sOPCA but 
not in patients with MSAsDs or dOPCA. Since FMZ 
Table 5. Flumazenil Distribution Volume, Normalized to the Cerebral Cortex (mean ? standzrd errorla 
Normal 
Controls MSAOPC.4 MSASDS sOPCA dOPCA 
Structure (n = 20) (n = 14) (n = 5 )  (n = 18) (n = 17)  
Caudate nuclei 0.59 ? 0.03 0.59 5 0.04 0.56 ? 0.06 0.57 ? 0.03 0.56 -t 0.03 
Putamen 0.67 f 0.02 0.72 +- 0.03 0.66 ? 0.04 0.67 ? 0.02 0.65 2 0.02 
Thalamus 0.69 rfr 0.02 0.68 0.03 0.66 ? 0.04 0.66 ? 0.02 0.67 * 0.02 
Cerebellar hemispheres 0.78 f 0.03 0.87 2 0.06 0.79 =k 0.08 0.77 -t 0.04 0.76 +- 0.04 
Cerebellar vermis 0.69 * 0.02 0.68 +- 0.04 0.68 ? 0.06 0.57 +- 0.03b 0.61 ? 0.03 
Brainstem 0.22 ? 0.01 0.21 f 0.01 0.22 2 0.02 0.20 ? 0.01 0.21 f 0.01 
‘Abbreviations are as in Table 1. 
bSignificantly different from normal controls at p < 0.01. 
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influx depends strongly on cerebral blood flow (CBF), 
these findings suggest that CBF is decreased in the 
cerebellum of patients with the ataxic form of MSA 
(MSA,,,,) as well as both sporadic and dominantly 
inherited OPCA, but not in the extrapyramidal/auto- 
nomic form of MSA (MSA,,,). The decline of CBF 
values in these disorders probably results at least in 
part from partial volume effects related to tissue at- 
rophy. 
Despite the finding of diminished FMZ influx into 
the cerebellum in MSAOpCA, sOPCA, and dOPCA and 
into the cerebellum and brainstem in MSAopCA and 
sOPCA, DV was unchanged in all the structures stud- 
ied, including the cerebellum and brainstem, except 
for a significant decrease in the cerebellar vermis in 
sOPCA with data normahzed to the cerebral cortex. 
The decreased DV normalized to cerebral cortex in 
the cerebellar vermis in sOPCA resulted from the 
combination of a nonsignificant 11% decrease in abso- 
lute DV in the cerebellar vermis and a nonsignificant 
7% increase in DV in the cerebral cortex. We cannot 
determine whether this finding is spurious, given that 
it results from the combination of a decrease in one 
region and an increase in another, or whether it reflects 
pathological involvement of neurons bearing BDZ re- 
ceptors in the cerebellar vermis in sOPCA patients. 
Subclinical striatal degeneration occurs frequently in 
OPCA, and thus it is interesting that striatal FMZ 
K ,  and DV values were normal in all patient groups. 
The substantial numbers of patients in the sOPCA, 
dOPCA, and MSAopcA groups and the power analysis 
lend credence to the findings in these patients, but 
with the small sample and relatively low power in the 
MSA,,, group, we do not view the results in this one 
group as definitive. 
The cerebellar hemispheres, vermis, and brainstem 
are known to be decreased in volume in many patients 
with MSA or OPCA. Our methods do not permit de- 
termination of the extent to which atrophy affects our 
results. The method we used for analysis, that of plac- 
ing a VOI of standard shape and size over the local 
peak of activity, is less sensitive to atrophy than are 
other methods. Nonetheless, it is possible that tissue 
atrophy partially accounts for our finding that some of 
the K ,  measurements in the cerebellar hemispheres, 
vermis, and brainstem are decreased in MSAOpcA, 
sOPCA, and dOPCA patients. Our measurements of 
DV generally showed no change, indicating little or no 
loss of BDZ receptors in these disorders. “Correcting” 
PET results to account for the effects of atrophy is an 
imprecise process, but had we attempted this, in all 
likelihood we would have found less prominent reduc- 
tions in K,. Me cannot exclude the possibility that “cor- 
recting” the DV results would have yielded findings of 
increased DV per gram of tissue; the interpretation of 
such a finding would be that GABAA/BDZ receptors 
are relatively spared in comparison to other tissue ele- 
ments that are lost. 
Shinotoh and colleagues 1551 studied BDZ receptor 
binding with [ ”CIFMZ and PET in a previous investi- 
gation of OPCA. This investigation revealed signifi- 
cantly increased binding (at the p < 0.01 level) in the 
cerebellar cortex of 7 patients with sOPCA as com- 
pared with 6 normal control subjects. In the same 
study, BDZ receptor binding was decreased in the cer- 
ebellar cortex of 4 patients thought to have cerebellar 
cortical atrophy (CCA) in comparison with the normal 
control subjects, but this difference was not statistically 
significant. The findings in the present study did not 
confirm those of Shinotoh and colleagues 1551. Factors 
that might explain the disparity between the two stud- 
ies include their separation of patients into OPCA and 
CCA groups, biological differences between subjects 
in the two studies, and the considerably larger number 
of patients in the present study. 
Only two investigations utilizing postmortem brain 
tissue characterized the density of GABAA/BDZ re- 
ceptors in the cerebellum in MSA, and the findings in 
both studies are compatible with the results of the pres- 
ent investigation. In an autoradiographic study using 
I3H1flunitrazepam, Whitehouse and coworkers I561 
found normal BDZ binding in the cerebellar cortex 
and increased binding in the dentate nuclei in 4 pa- 
tients with cerebellar degeneration. Although all pa- 
tients were labeled as having OPCA, 3 of the 4 met 
criteria for MSA of the ataxic type since their disorders 
were sporadic and were characterized by a progressive 
ataxia of gait, parkinsonism, and a mild terminal de- 
mentia. In a recent autoradiographic study of MSA, 
GABAA binding sites were unchanged in the molecu- 
lar layer but significantly decreased in the granule cell 
layer C571. BDZ binding and GABA, binding were 
unchanged in both layers. In the dentate nucleus, 
GABA, binding and BDZ binding were significantly 
increased. 
Neurochemical studies of postmortem brain tissue 
in dOPCA demonstrated several different biochemical 
profiles of amino acid levels C58, 591. Most of these 
profiles include decreased glutamate, aspartate, and 
GABA levels in the cerebellar cortex and decreased 
GABA levels in the dentate nucleus. These profiles 
probably represent differences in the degree of degen- 
eration of particular types of neurons among various 
cases of OPCA C601. 
The results of three studies of GABAA/BDZ recep- 
tor binding in OPCA have been reported [56,61,62), 
and they are conflicting. Using C3H1flunitrazepam as a 
ligand, Kish and associates 1621 found that BDZ recep- 
tor binding was either normal or slightly elevated in 
the cerebellar cortex. Binding in the deep cerebellar 
nuclei was not studied. As mentioned already, 
Whitehouse and coworkers 1561 found that BDZ re- 
Gilman el d: Benzodiazepine Receptor Binding 183 
ceptor binding was unchanged in the cerebellar cortex, 
but increased in the dentate nucleus. Using in vitro 
postmortem autoradiography with E3H]flunitrazepam 
and I3H]GABA, Albin and Gilman 1631 found a 
marked decrease of binding in the cerebellar cortex of 
4 patients with OPCA. The reason the findings of Al- 
bin and Gilman [631 are different from those of Kish 
and associates [62] and Whitehouse and coworkers 
[56] may relate to biochemical differences between 
patients, probably because of variations in the degree 
of degeneration of the various types of neurons in the 
cerebellar cortex [58-GO]. 
The principal conclusion from the present study is 
that BDZ receptors are largely preserved in the cere- 
bellar cortex, brainstem, and basal ganglia in MSA, 
sOPCA, and dOPCA despite the known degenerative 
changes in many of these structures in these disorders. 
This finding is potentially important therapeutically, 
since it indicates that pharmacological interventions fo- 
cused on GABA,/BDZ receptors might offer some 
hope of alleviating the cerebellar and extrapyramidal 
symptoms of these disorders. 
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